Published online Aug 15, 2025. doi: 10.4239/wjd.v16.i8.106664
Revised: April 30, 2025
Accepted: July 4, 2025
Published online: August 15, 2025
Processing time: 163 Days and 8.8 Hours
Apolipoprotein E epsilon 4 (APOE4) is recognized as a genetic risk factor for cognitive decline and neurodegeneration in both type 2 diabetes mellitus (T2DM) and Alzheimer’s disease, while glycated hemoglobin (HbA1c) reflects persistent hyperglycemia and serves as a key indicator of long-term glycemic control in T2DM. Although both factors have been individually linked to neurobehavioral deficits, it remains uncertain whether HbA1c contributes to APOE4-related cognitive and olfactory impairment in individuals with T2DM.
To investigate the role of HbA1c in APOE4-associated cognitive and olfactory dysfunction in patients with T2DM.
Of 636 T2DM patients were recruited from five medical centers in Wuhan, Hubei Province, China. APOE geno
APOE4 was associated with increased risks of cognitive impairment [odds ratios (OR) = 1.815, P = 0.021] and olfac
Elevated HbA1c levels are associated with increased risks of cognitive and olfactory impairments in patients with T2DM and may exacerbate the detrimental effects of APOE4. These findings underscore the need for early pre
Core Tip: This study explores how the apolipoprotein E epsilon 4 (APOE4) genotype and glycated hemoglobin (HbA1c) levels influence cognitive and olfactory performance in individuals with type 2 diabetes mellitus. The findings suggest that APOE4 is linked to both cognitive and olfactory deficits, and that elevated HbA1c levels further intensify these effects. Rather than serving as a mediator, HbA1c modifies the relationship, strengthening the adverse impact of APOE4. These results indicate that both APOE4 and poor glycemic control contribute to neurofunctional decline, underscoring the importance of early intervention in at-risk diabetic populations.